<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210617051606N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-10-27</date_registration>
      <primary_sponsor>Razi University</primary_sponsor>
      <public_title>Effects of exercise training and vitamin D supplementation on Migraine</public_title>
      <acronym></acronym>
      <scientific_title>Effects of 8 weeks of aerobic exercise and vitamin D supplementation on serum levels of brain-derived neurotrophic factor, quality of life, and some cognitive and psychological indices in Migraine patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58967</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, permuted block randomization via the www.randomization.com website will be used. To do so, first, a unique number will be allocated to each subject as the identifier code and, a 48-digit sequence (equal to sample size) will be created. Then, treatment labels including 1) Exercise + Vitamin D group; 2) Exercise + Placebo group; 3) Vitamin D group, and 4) Control group will be entered in the relevant section on the website. After defining the treatment groups and to avoid potential problems associated with equal block sizes, permuted block randomization with differents block sizes will be applied. In this case, by knowing the sample size, the block sizes will be unequal and a multiple of the number of treatment groups (for example, block sizes of 2, 4, 6, or 8). The website has the ability to randomly specify the sequence of blocks with different sizes. In the final step and upon performing the 'Generate Plan' on the website, all subjects will be randomly assigned to blocks of different sizes that already have a random sequence. Finally, the group (treatment) of each subject will be specified by the use of the identifier code and checking out the blocks, Blinding description: The present study is single-blind in which participants are blinded about receiving vitamin D or placebo while, based on the nature of exercise training, there will be no blinding for exercise interventions. For blinding 2 groups not receiving vitamin D, tablets with identical characteristics, color, taste, and smell with vitamin D tablets will be prepared as the placebo, and none of the subjects will be aware of the status of the supplementation.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Migraine without aura.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: continuous aerobic exercise for 8 weeks and 3 sessions per week. In the first week, the duration of training will be 20 minutes and the intensity will be 50% of heart rate reserve. Gradually, the time and intensity of training increase, and at week 8, the time of training will be 40 minutes and the intensity will be 60% of heart rate reserve. This group also receives 50000 International Units of vitamin D in the form of oral tablets every week. Intervention 2: Intervention group: continuous aerobic exercise for 8 weeks and 3 sessions per week. In the first week, the duration of training will be 20 minutes and the intensity will be 50% of heart rate reserve. Gradually, the time and intensity of training increase, and at week 8, the time of training will be 40 minutes and the intensity will be 60% of heart rate reserve. This group also receives placebo tablets identical to vitamin D tablets every week. Intervention 3: Intervention group: This group receives 50000 International Units of vitamin D in the form of oral tablets every week for 8 weeks. Intervention 4: Control group: Normal life during the study plus receiving placebo tablets identical to vitamin D tablets every week.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data are shared after the de-identification of the participants

When:
3 months after publication

To whom:
All individuals upon formal request

Conditions:
Data sharing requests are accepted for any purposes

Where to obtain:
To obtain any data/document, please send an e-mail to Ehsan Amiri, a faculty member at Razi University, through the following e-mail address: e.amiri@razi.ac.ir

How to obtain:
Upon formal request, mentioning due reasons, and providing full personality details, data will be sent after 72 h via e-mail

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ehsan Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 73, Faculty of Sport Sciences, Razi University, Tagh-e-Bostan, University St., Kermanshah, Iran</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3845 8428</telephone>
        <email>e.amiri@razi.ac.ir</email>
        <affiliation>Razi University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ehsan Amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 73, Faculty of Sport Sciences, Razi University, Tagh-e-Bostan, University St., Kermanshah, Iran</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714414971</zip>
        <telephone>+98 83 3845 8428</telephone>
        <email>e.amiri@razi.ac.ir</email>
        <affiliation>Razi University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Not participation in regular exercise over the last 6 months
Having Migraine without aura confirmed by a specialist
Getting the certification of no prohibition of participating in the exercise training program from a specialist
Insufficient values of Vitamin D (20-29 nanograms/milliliter)
Aged between 20 to 50 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>Any psychiatric disorders other than Migraine without aura
Alcohol and other kinds of drug addiction
Musculoskeletal disorder
Cardiovascular and pulmonary diseases
Refusal to give informed consent</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G43.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Migraine without aura</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: continuous aerobic exercise for 8 weeks and 3 sessions per week. In the first week, the duration of training will be 20 minutes and the intensity will be 50% of heart rate reserve. Gradually, the time and intensity of training increase, and at week 8, the time of training will be 40 minutes and the intensity will be 60% of heart rate reserve. This group also receives 50000 International Units of vitamin D in the form of oral tablets every week.</i_keyword>
      <i_keyword>Intervention group: continuous aerobic exercise for 8 weeks and 3 sessions per week. In the first week, the duration of training will be 20 minutes and the intensity will be 50% of heart rate reserve. Gradually, the time and intensity of training increase, and at week 8, the time of training will be 40 minutes and the intensity will be 60% of heart rate reserve. This group also receives placebo tablets identical to vitamin D tablets every week.</i_keyword>
      <i_keyword>Intervention group: This group receives 50000 International Units of vitamin D in the form of oral tablets every week for 8 weeks.</i_keyword>
      <i_keyword>Control group: Normal life during the study plus receiving placebo tablets identical to vitamin D tablets every week.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Change in serum levels of brain-derived neurotrophic factor. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By the use of blood sample and ELISA method.</prim_outcome>
      <prim_outcome>Change in quality of life. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: World health organization standard quality of life questionnaire (short version).</prim_outcome>
      <prim_outcome>Changes in severity, duration, and frequency of Migraine attacks. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By the use of researcher-made questionnaire to record the pertinent variables of Migraine attacks.</prim_outcome>
      <prim_outcome>Changes in memory performance. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By the use of Subjective Memory Complaints Scale.</prim_outcome>
      <prim_outcome>Changes in cognitive performance. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By the use of Ascertain Dementia 8 (AD8) questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Changes in depression severity. Timepoint: Before starting the intervention, and 8 weeks after starting the intervention. Method of measurement: By the use of Beck’s Depression Inventory.</sec_outcome>
      <sec_outcome>Change in the quality of sleep. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Pittsburgh Sleep Quality Index.</sec_outcome>
      <sec_outcome>Change in physical self-concept. Timepoint: Before intervention and after 8 weeks of intervention. Method of measurement: Physical self-concept questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Razi University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-02</approval_date>
        <contact_name>Research Ethics Committees of Kermanshah Razi University</contact_name>
        <contact_address>Room. 73, Faculty of Sport Sciences, Razi University, University Str, Taq-e-bostan, Kermanshah, Iran Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
